ArticleHerz2026
Atherogenic index as an associative marker for coronary artery disease.
Article in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary artery disease (CAD) is a significant global health burden, warranting pragmatic, low-cost biomarkers for effective risk stratification. The atherogenic index of plasma (AIP), calculated as log(TG/HDL-C), is a lipid-derived indicator of cardiometabolic risk. We evaluated AIP as an associative marker for CAD and compared its diagnostic performance with commonly used biomarkers.
methodsIn a hospital-based, angiography-confirmed case-control cohort (n = 340; 211 cases, 129 controls), we assessed AIP alongside uric acid, creatinine, neutrophil-to-lymphocyte ratio (NLR), TG/HDL‑C, HbA1c, and ejection fraction. Group characteristics were summarized using descriptive statistics, chi-square tests, and ANOVA. Associations with CAD were examined using multivariable logistic regression adjusted for age, sex, body mass index, diabetes, hypertension, smoking status, and statin use. Discriminative performance was evaluated via receiver operating characteristic (ROC) analysis, with pairwise comparisons conducted using DeLong's test.
resultsValues of AIP (OR 1.42, 95% CI 1.18-1.69; p = 0.012), uric acid (OR 1.20, 95% CI 1.02-1.42; p = 0.032), and creatinine (OR 1.69, 95% CI 1.03-2.76; p = 0.038) were independently associated with CAD. HbA1c, TG/HDL‑C, NLR, and ejection fraction were not significantly associated in multivariable models. Values of AIP increased with greater angiographic severity. In ROC analysis, AIP showed superior discriminatory ability to uric acid, creatinine, NLR, and HbA1c (all p < 0.05, DeLong test), and performed comparably to TG/HDL‑C, consistent with AIP being its log transformation.
conclusionReadily available AIP offers incremental prognostic value in symptomatic patients with suspected CAD. These findings are hypothesis-generating; thus, thresholds should be interpreted cautiously pending prospective, multicenter studies.
Indexed as
Identifiers
41511533What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.